LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Captures 60% of New GLP-1 Prescriptions as Morgan Stanley Reaffirms Overweight Rating
Morgan Stanley reiterated its Overweight rating for Eli Lilly and Company. The investment bank maintained a price target of $1,313 per share. Prescriptions...
🔴 LLY is trading 3.4% down today on geopolitical tensions and a broader market selloff
LLY is trading at $969.90 (-3.4%) as geopolitical tensions and profit-taking drive a sharp decline across major indices. - Major indices are under pressure...
Eli Lilly Launches Employer Connect to Bridge Obesity Drug Coverage Gap for Millions of Workers
Eli Lilly and Company launched its Employer Connect platform on March 5, 2026. This initiative increases employee access to obesity medications through...
Eli Lilly Finalizes Acquisition of Ventyx Biosciences
Eli Lilly and Company finalized its acquisition of Ventyx Biosciences on March 4, 2026. Ventyx now operates as a wholly owned subsidiary. The transaction...
Eli Lilly's Pipeline Strength and Diversification Strategy Reassessed
Eli Lilly updated its pipeline in late February 2026. The company reported Phase 3 data for orforglipron, an oral GLP-1 candidate. The Zepbound KwikPen...
🔴 LLY is trading 3.14% down
LLY is trading at $1018.96, down 3.14%.
🔴 LLY is trading 3% down today as it underperforms a broader market recovery
LLY is trading at $1020.29 (-3.01%) as the stock lags behind a broader market recovery. - Major indices are trending higher, with the S&P 500 up 0.29% and the...
Eli Lilly Shares Fall as Novo Nordisk Commits $500M to Wegovy Pill Expansion
Eli Lilly shares fell approximately 2% on March 2, 2026. The decline followed reports that rival Novo Nordisk is investing over $500 million to expand...
Eli Lilly Oral GLP-1 Beats Novo Nordisk Rival in Phase 3 Trial Amid Tolerability Concerns
Eli Lilly's oral GLP-1 candidate, orforglipron, demonstrated superior efficacy compared to Novo Nordisk's Rybelsus in a head-to-head Phase 3 trial for adults...
Eli Lilly Wins Major Biotech Licensing Dispute, Avoiding $278M Payout
Eli Lilly won a licensing dispute regarding an alleged breach of agreement. The company avoided a $278 million payout. The verdict removes financial...
Eli Lilly Widens Lead in Obesity Market as Wall Street Bets on Oral GLP-1 Pipeline
JPMorgan, Deutsche Bank, and RBC Capital reiterated their confidence in Eli Lilly’s leadership within the expanding obesity treatment market. The investment...
Lilly’s Oral Orforglipron Outperforms Novo’s Semaglutide in Landmark Head-to-Head Trial
Eli Lilly’s experimental once-daily oral drug, orforglipron, demonstrated superior efficacy over Novo Nordisk’s oral semaglutide in a Phase 3 head-to-head...
Eli Lilly Shares Slide as Novo Nordisk Signals 50% Price Cuts for GLP-1 Rivals
Eli Lilly (LLY) shares declined in premarket trading following a pricing announcement from primary rival Novo Nordisk. Novo Nordisk plans to reduce prices for...
Eli Lilly Stock Jumps on Zepbound KwikPen Approval as Rival Novo Nordisk Tumbles 16%
Eli Lilly and Company received U.S. FDA approval for the Zepbound KwikPen, a multi-dose injector for its weight-loss medication. This new device delivers four...
Eli Lilly Shares Surge as Novo Nordisk Weight-Loss Trial Fails
Eli Lilly (LLY) shares surged 4.84% to close at $1058.39 following a clinical setback for competitor Novo Nordisk and the official launch of the Zepbound...
🟢 LLY is trading 3.16% up today after Mounjaro outperforms Novo Nordisk's CagriSema in head-to-head trial
LLY is trading at $1041.44 (+3.16%) after its obesity drug Mounjaro outperformed Novo Nordisk's CagriSema in a head-to-head Phase 3 trial. • The study...
🟢 LLY is trading 2.72% up today as Mounjaro outperforms Novo Nordisk's CagriSema in head-to-head study
LLY is trading at $1037.00 (+2.72%) in pre-market action after Eli Lilly's Mounjaro outperformed Novo Nordisk's rival drug CagriSema in a head-to-head clinical...
Barclays Initiates Overweight Coverage on Eli Lilly with $1,350 Target
Barclays initiated coverage on Eli Lilly (LLY) with an Overweight rating and a $1,350 price target, reflecting continued bullish sentiment following several...
Eli Lilly’s Omvoh Maintains 92% Remission in Crohn’s Disease Through Three Years
Eli Lilly released three-year Phase 3 data for its Crohn's disease treatment, Omvoh (mirikizumab). The study found that 92.4% of patients who responded to...
Eli Lilly Combination Therapy Achieves Superior Skin Clearance and Weight Loss in Phase 3b Psoriasis Trial
Eli Lilly and Company reported positive topline results from the TOGETHER-PsO Phase 3b clinical trial. The study evaluated Zepbound (tirzepatide) combined with...